Albuterol · Albuterol Sulfate, Albuterol Sulfate Hfa

What is Albuterol?

Albuterol is a short-acting beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP. This leads to smooth muscle relaxation and bronchodilation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Albuterol Sulfate, Albuterol Sulfate Hfa, Proair Hfa, Proventil, A004, A006, Proventil-HFA

Drug type

Small molecule

Targets

beta-2 adrenergic receptor (ADRB2), beta-1 adrenergic receptor (ADRB1) (secondary target)

Mechanism

Agonist of beta-2 adrenergic receptor (ADRB2)

Pathways

cAMP signaling, bronchial smooth muscle relaxation

Therapy area

Respiratory

Developer

Schering

In trials of

AMPH, SPRY

FDA status

Approved as Albuterol Sulfate, Albuterol Sulfate Hfa, Proair Hfa (July 13, 1987), NDA019383 · FDA label

UNII

5F9MRH56GE

✅ FDA-approved uses

• Treatment or prevention of bronchospasm in reversible obstructive airway disease (Albuterol Sulfate Hfa)
• Prevention of exercise-induced bronchospasm (Albuterol Sulfate Hfa)

From the indications section of the FDA label (version of Dec 31, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AsthmaBronchospasmChronic Obstructive Pulmonary Disease (COPD)

Other drugs acting on ADRB2

Sources

• FDA label (DailyMed)
• FDA label Albuterol Sulfate Hfa (2024-12-31), indications
• FDA label Albuterol Sulfate (2023-10-01), indications
• NCI Thesaurus
• NCI Thesaurus
• ClinicalTrials.gov NCT00634517
• ClinicalTrials.gov NCT00634829
• ClinicalTrials.gov NCT00634829
• ClinicalTrials.gov NCT01174732

Updated Oct 3, 2026.